Citation Impact
Citing Papers
TOR Signaling in Growth and Metabolism
2006 Standout
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients
2002
Gout: On the brink of novel therapeutic options for an ancient disease
2004
A Retrospective Review of Liver Transplant Patients Treated with Sirolimus from a Single Center: An Analysis of Sirolimus-Related Complications
2004
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
2002 Standout
Early cyclosporine a withdrawal in kidney transplant recipients under a sirolimus-based immunosuppressive regimen: pathological study of graft biopsies at 1-year posttransplant
2002
Delayed graft function in kidney transplantation
2004 Standout
mTOR Signaling in Growth Control and Disease
2012 Standout
Severe Diarrhea in Renal Transplant Patients: Results of the DIDACT Study
2006
Myasthenia Gravis
2016 Standout
Glucose Metabolism in Renal Transplant Recipients
2005
SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12
2000
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
2000 Standout
Simultaneous Administration of Adjuvant Donor Bone Marrow in Pancreas Transplant Recipients
1999
Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent
2002
Pharmacokinetic Interactions Augment Toxicities of Sirolimus/Cyclosporine Combinations
2001
SIROLIMUS-INDUCED THROMBOCYTOPENIA AND LEUKOPENIA IN RENAL TRANSPLANT RECIPIENTS: RISK FACTORS, INCIDENCE, PROGRESSION, AND MANAGEMENT12
2000
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
2002 Standout
WOUND-HEALING COMPLICATIONS AFTER KIDNEY TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED COMPARISON OF SIROLIMUS AND TACROLIMUS1
2004
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
2007 Standout
Pathology of Drug-Eluting Stents in Humans
2006 Standout
Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials
2006
Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview
2006
Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs
2006
Rapamycin in transplantation: A review of the evidence
2001
Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation
2008
Dialysis, Transplantation, and Pregnancy
1991
A PILOT STUDY OF STEROID-FREE IMMUNOSUPPRESSION IN THE PREVENTION OF ACUTE REJECTION IN RENAL ALLOGRAFT RECIPIENTS
2001
Functional and morphological study of cultured pancreatic islets treated with cyclosporine
2006
A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS
2001
Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity
2000
Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient
2005
Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation1
2003
PROMISING EARLY OUTCOMES WITH A NOVEL, COMPLETE STEROID AVOIDANCE IMMUNOSUPPRESSION PROTOCOL IN PEDIATRIC RENAL TRANSPLANTATION1
2001
Gout
2009 Standout
The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway
2017
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors.
1992
Addition of Sirolimus to Cyclosporine Delays the Recovery from Delayed Graft Function but Does not Affect 1-Year Graft Function
2004
Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination1, 2
2002
ESTABLISHMENT OF STABLE MULTILINEAGE HEMATOPOIETIC CHIMERISM AND DONOR-SPECIFIC TOLERANCE WITHOUT IRRADIATION1
2000
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
2008 Standout
Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens
2001
Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation
2003
Chronic Renal Failure after Transplantation of a Nonrenal Organ
2003 Standout
Calcineurin Inhibitor Avoidance with Daclizumab, Mycophenolate Mofetil, and Prednisolone in DR-Matched de Novo Kidney Transplant Recipients
2006
Diabetes Mellitus after Kidney Transplantation in the United States
2003 Standout
Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery
2006 Standout
Early Adequate Mycophenolic Acid Exposure is Associated with Less Rejection in Kidney Transplantation
2004
A Prospective, Randomized Trial of Tacrolimus in Combination with Sirolimus or Mycophenolate Mofetil in Kidney Transplantation: Results at 1 Year
2005
Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients
2003
RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1
2001
Graft-versus-host disease
2009 Standout
High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study
2016
Clinical Pharmacokinetics of Tacrolimus
1995 Standout
Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine nephrotoxicity
2004
Tuberous sclerosis
2008 Standout
De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years
2004
Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation
2003
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
2006 Standout
Gout in Solid Organ Transplantation
2005
Type 1 diabetes
2013 Standout
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
2007 Standout
Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation
2005
Regulatory T cells in transplantation tolerance
2003 StandoutNobel
Sirolimus(rapamycin) allows renal recovery in lung and heart transplant recipients with chronic renal impairment
2001
Delayed Graft Function and Cast Nephropathy Associated with Tacrolimus Plus Rapamycin Use
2003
A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
2010 Standout
Acute Pancreatitis
1994 Standout
Strategies to Improve Long-Term Outcomes after Renal Transplantation
2002 Standout
Prednisone‐Free Maintenance Immunosuppression—A 5‐Year Experience
2005
Clinical application of sirolimus in renal transplantation: an update
2005
MYCOPHENOLATE MOFETIL REDUCES LATE RENAL ALLOGRAFT LOSS INDEPENDENT OF ACUTE REJECTION
2000
Management of Chronic Allograft Nephropathy
2009
Costimulation Blockade with Belatacept in Renal Transplantation
2005 Standout
A CALCINEURIN ANTAGONIST-FREE INDUCTION STRATEGY FOR IMMUNOSUPPRESSION IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS AT RISK FOR DELAYED GRAFT FUNCTION1
2001
Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen
2000 Standout
Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients
2003 Standout
Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients
2008 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
2002 Standout
Uric acid and transplantation
2005
Effects of Sirolimus on Lipids in Renal Allograft Recipients: An Analysis Using the Framingham Risk Model
2002
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. Ii. Survival, function, and protocol compliance at 1 year
2004
mTOR-targeted therapy of cancer with rapamycin derivatives
2005
SIROLIMUS REDUCES THE INCIDENCE OF ACUTE REJECTION EPISODES DESPITE LOWER CYCLOSPORINE DOSES IN CAUCASIAN RECIPIENTS OF MISMATCHED PRIMARY RENAL ALLOGRAFTS: A PHASE II TRIAL1
1999
The PI3K Pathway in Human Disease
2017 Standout
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
1995 Standout
Infection in Solid-Organ Transplant Recipients
2007 Standout
Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of Steroids
2007
Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1
2003
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients
2008
Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery
2003 Standout
Immunosuppressive Drugs for Kidney Transplantation
2004 Standout
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
2008 Standout
Immunosuppressive strategies in transplantation
1999
Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion
2009 StandoutNobel
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation
2004
Review of the proliferation inhibitor everolimus
2002
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1
2002
Purified hematopoietic stem cells can differentiate into hepatocytes in vivo
2000 Standout
Human pancreatic tissue concentration of bactericidal antibiotics
1992
Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence
2012
Chronic viral hepatitis and the management of chronic renal failure
1995
Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study
2007
Management and Prevention of Cytomegalovirus Infection After Renal Transplantation
1992
Detection and identification of bacterial DNA in serum from patients with acute pancreatitis
2005
Gut Microbiota in Health and Disease
2010 Standout
Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease
2002
Correlative imaging of ionic transport and electronic structure in nano Li0.5FePO4 electrodes
2019 StandoutNobel
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent
2004
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
2006
Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents
2001
Delayed Wound Healing with Sirolimus after Liver Transplant
2002
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
2003 Standout
Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries
2001
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
2004
Distinct Signaling Events Downstream of mTOR Cooperate To Mediate the Effects of Amino Acids and Insulin on Initiation Factor 4E-Binding Proteins
2005 StandoutNobel
Entry‐into‐human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients
1999
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
2000
Works of C Brattström being referenced
Penetration of pefloxacin into human allograft pancreatic juice
1990
Hypertriglyceridemia in renal transplant recipients treated with sirolimus
1998
Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—A Swedish population‐based study
2012
A Simple HPLC Method for Simultaneous Determination of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Plasma
1999
SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATION
1999 Standout
New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation
1998
Determination of Rapamycin in Whole Blood by HPLC
1997
A 10-year prospective study of IDDM patients subjected to combined pancreas and kidney transplantation or kidney transplantation alone
1997
Can antibody prophylaxis allow sparing of other immunosuppressives?
1999
Kinetics and Dynamics of Single Oral Doses of Sirolimus in Sixteen Renal Transplant Recipients
1997
High frequency of hepatitis B virus DNA in anti‐HBe positive sera on longitudinal follow‐up of patients with renal transplants and chronic hepatitis B
1989
Immunoglobulin G subclasses and lymphocyte stimulatory responses to cytomegalovirus in transplant patients with primary cytomegalovirus infections
1992
A 10 Year Prospective Study of IDDM Patients Subjected to Combined Pancreas and Kidney Transplantation or Kidney Transplantation Alone
1998
Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the sirolimus European renal transplant study
2003
MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION
2001
Penetration of ciprofloxacin and ofloxacin into human allograft pancreatic juice
1988
SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10
2001
134 TACROLIMUS (FK506) KINETICS IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS
1995
Metabolic effects of living related pancreatic graft donation.
1988
Early antibiotic treatment in acute necrotising pancreatitis
1995
Penetration of clindamycin, cefoxitin, and piperacillin into pancreatic juice in man.
1988
PRELIMINARY RESULTS OF THE COMBINED USE OF A HUMANIZED ANTI-IL-2Rα MONOCLONAL ANTIBODY, DACLIZUMAB (DZB), AND MYCOPHENOLATE MOFETIL (MMF) WITHOUT CALCINEURIN INHIBITORS IN RENAL TRANSPLANTATION
1998
Metabolic control at two months to 4.5 years after pancreatic transplantation, with special reference to the role of cyclosporine.
1987
A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
1996
Pregnancy After Combined Pancreas-Kidney Transplantation
1989